First US cell-based flu vaccine plant underway
Novartis last week began construction of a major new flu vaccine manufacturing facility in North Carolina, the very first cell culture-derived flu vaccine plant in the United States.
Novartis last week began construction of a major new flu vaccine manufacturing facility in North Carolina, the very first cell culture-derived flu vaccine plant in the United States.
Sanofi-Aventis has been hit with its second patent lawsuit in two months over its recently released SoloStar insulin pen.
Big pharma is learning from past failures to improve its ability to predict drug toxicity earlier in the development process.
A new device has been developed enabling researchers to study the stability of therapeutic proteins against shear stresses to allow better bioprocess optimisation.
New data have raised 'serious questions' about whether Arpida's new antibiotic will be approved by industry regulators, according to one analyst's report.
Covance, PharmaNet, Quintiles, PPD, Kendle and Clinsys have all had people on the move in the world of pharmaceutical outsourcing.
Nicholas Piramal is the latest Indian pharma firm planning to spin off its new chemical entity (NCE) research unit as its pipeline is maturing.
Investment mogul Carl Icahn could get ready to buy further shares of biotech company Biogen Idec after getting the green light from the competition regulators.
The UK arm of biopharma company ProMetic has hit a milestone with its breakthrough synthetic molecule solution for protein purification.
In a round up of the latest news in pharma research, Pfizer and Bristol-Myers Squibb have big plans for DGAT-1 in obesity and diabetes, GlaxoSmithKline is extra keen on Exelixis' anticancer drug, Takeda is talking TLRs and UK scientists have made 'a...